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Abstract
Peritoneal carcinomatosis (PC) from epithelial tumors is a fatal diagnosis without efficient
treatment. Trifunctional antibodies (trAb) are novel therapeutic approaches leading to a concerted
anti-tumor activity resulting in tumor cell destruction. In addition, preclinical data in mouse tumor
models demonstrated the induction of long lasting tumor immunity after treatment with trAb. We
describe the induction of anti-tumor specific T-lymphocytes after intraperitoneal administration of
trAb in patients with PC.
9 patients with progressive PC from gastric (n = 6) and ovarian cancer (n = 2), and cancer of
unknown primary (n = 1) received 3 escalating doses of trAb after surgery and/or ineffective
chemotherapy. The trAb EpCAM × CD3 (10, 20, 40 μg) or HER2/neu × CD3 (10, 40, 80 μg) were
applicated by intraperitoneal infusion. Four weeks after the last trAb application, all patients were
restimulated by subdermal injection of trAb + autologous PBMC + irradiated autologous tumor
cells. Immunological reactivity was tested by analyzing PBMC for specific tumor reactive CD4+/
CD8+ T lymphocytes using an IFN-γ secretion assay.
In 5 of 9 patients, tumor reactive CD4+/CD8+ T-lymphocytes increased significantly, indicating
specific anti-tumor immunity. A clinical response (stable disease, partial regression) has been
observed in 5 of 9 patients, with a mean time to progression of 3.6 months. Follow-up showed a
mean survival of 11.8 months (median 8.0 months) after trAb therapy.
TrAb are able to induce anti-tumor immunity after intraperitoneal application and restimulation.
The induction of long-lasting anti-tumor immunity may provide an additional benefit of the
intraperitoneal therapy with trAb and should be further elevated in larger clinical trials.
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Background
Peritoneal carcinomatosis (PC) is a common dissemi-
nated type of gastric and ovarian cancer. It is associated
with a poor prognosis with a median survival of only few
months [1,2]. PC is accompanied by obsessing symptoms
like malignant ascites and ileus due to abdominal
obstruction, which is treated by paracentesis or palliative
surgery. No efficient standard treatment to prevent or
eradicate peritoneal spread is available so far. Conven-
tional intravenous (i.v.) chemotherapy was generally not
effective [3,4]. Various experimental and multimodal con-
cepts have been evaluated including peritonectomy proce-
dures[5,6], hyperthermic intraperitoneal (i.p.)
chemotherapy [7,8] or immediate postoperative i.p.
chemotherapy [9,10]. All these concepts indicated that
local treatment procedures might represent the best
option for treatment of PC.
New therapeutic concepts employ trifunctional antibod-
ies (trAb) that recruit and activate different types of
immune effector cells at the tumor site. TrAb are artifi-
cially engineered immunoglobulins with two different
Fab-binding sites and an intact Fc-region [11] and repre-
sent a novel antibody concept [12]. They effectively
enhance the anti-tumor activity not only by induction of
T-cells by CD3-binding, but also by simultaneous activa-
tion of accessory cells [13,14]. Responsible for this feature
is a potent isotype combination (mouse IgG2a and rat
IgG2b), which binds and activates FcγRI and RIII positive
cells (e.g. dendritic cells, macrophages, granulocytes and
NK-cells). The tri-cell complex of T-lymphocytes, tumor
cells and accessory cells induces efficient tumor cell kill-
ing, which results from an activating "crosstalk" via
cytokines (like e.g. IL-2, IL-12 and TNF-α) and costimula-
tory molecules between different immune cell types [13].
Therefore, trAbs are able to activate cell-mediated cytotox-
icity leading to MHC-unrestricted but specific killing of
targeted tumor cells without requirement for any pre-acti-
vation or co-stimulation. Moreover, involvement and
activation of Fcγ RI/III positive professional antigen pre-
senting cells results in phagocytosis of tumor cells and
subsequent induction of anti-tumor immunity by tumor
antigen processing and presentation [14,15]. This phe-
nomenon was supposed to result in polyclonal humoral
and cellular immune responses, including T-cell
responses even against unknown, tumor-associated pep-
tides. This hypothesis was confirmed in a syngeneic
mouse tumor model, where i.p. treatment with trAb dem-
onstrated striking anti-tumor effects including tumor
destruction and long term immunity, which where inde-
pendent of the primary tumor binding site of the appli-
cated trAb [15]. The trAb catumaxomab has dual specifity
for epithelial cell adhesion molecule (EpCAM) and CD3;
ertumaxomab targets epidermal growth factor family
member (HER2/neu) and CD3. EpCAM is frequently
expressed in different gastrointestinal malignancies like
colon and stomach and in lung and ovarian cancer
[16,17], HER2/neu is overexpressed in breast cancer [18].
EpCAM and HER2/neu are both a prognostic marker and
a target antigen [19,20].
In a previous study, we could demonstrate in vivo cytotox-
icity mediated by trAb catumaxomab in patients with
malignant ascites [21]. A multicenter phase I/II study
showed that an i.p. immunotherapy with catumaxomab
prevented accumulation of ascites and eliminated tumor
cells with an acceptable safety profile [22].
In this prospective pilot study, we investigated the induc-
tion of anti-tumor specific T-lymphocytes after i.p. admin-
istration and restimulation with trAb in patients with PC.
Patients and methods
Objectives and study approval
This study was designed as a sequential dose-escalating,
feasibility study for compassionate use of trAb in the
induction of tumor immunity.
The study was carried out according to the principles of
the Declaration of Helsinki and good clinical practice
guidelines. It was approved by the Ethics committee of the
Ludwig-Maximilians-University, Munich, Germany.
Informed consent was obtained from all patients prior to
treatment.
Patients
Patients enrolled in this study had histologically con-
firmed diagnosis of PC.
Inclusion criteria were Karnofsky performance status ≥
60%, white blood cell count > 2000/mm3 and a relative T-
cell count > 10%.
Exclusion criteria included prior immunotherapy, signifi-
cant heart disease or arrhythmia, known allergic reactions
or autoimmune disease, significant liver, kidney, pulmo-
nary or haematological disease, acute or chronical infec-
tion and paracentesis of malignant ascites > 1000 ml
within 30 days before treatment.
Patients were included independent of any prior conven-
tional therapy, i.e. chemotherapy, radiation or tumor sur-
gery. An interval of more than 30 days between any
chemotherapy and the start of the trAb therapy was
required. A recovery interval of at least 7 days after
abdominal surgery with laparotomy was mandatory.
All patients had a surgical procedure (explorative laparot-
omy or laparoscopy, resection of intra-abdominal metas-Journal of Experimental & Clinical Cancer Research 2009, 28:18 http://www.jeccr.com/content/28/1/18
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tases), where isolation of autologous tumor samples was
possible.
Isolation and storage of autologous tumor cells
Autologous tumor samples were taken during surgery
(explorative laparotomy or laparoscopy, resection of
intra-abdominal metastasis). The surgical procedure was
independent from study inclusion. Patients were only
included if more than 5 × 106 autologous tumor cells were
successfully isolated, and if EpCAM antigen or HER2/neu
antigen was found on > 10% of all viable cells from autol-
ogous tumor cell preparations.
Analysis of autologous tumor cells was performed by
immunohistochemical APAAP staining [23] using the
antibodies HO3 (anti-EpCAM; mouse IgG2a, TRION
Pharma) or C215 (anti EpCAM; mouse IgG2a; kindly pro-
vided by M. Dohlsten, Pharmacia, Uppsala, Sweden) for
EpCAM or 2502A (anti Her2/neu; mouse IgG2a; Trion
Pharma, Munich, Germany) for HER2/neu.
After surgical resection autologous tumor probes were dis-
sected into 2–3 mm3 pieces which were then immersed in
RPMI 1640 medium (containing 0.05% Collagenase type
4, 0.02% DNAse type 1, Penstrep, Gentamycin and
Amphotericin B; all reagents from Invitrogen, Carlsbad,
California). This mixture was incubated overnight at
37°C and filtered through a flexible grid to exclude undi-
gested tissue fragments. The resulting tumor cell suspen-
sion was washed twice with HBSS and resuspended in
RPMI 1640 medium (containing Glutamin and Pyruvate;
Invitrogen,) and 10% autologous serum at a concentra-
tion of 5 to 10 × 106 tumor cells. After cooling down to
4°C, 10% DMSO (PAN Biotech, Aidenbach, Germany)
was added. Then, standardized freezing by 1°C per
minute was performed using a computer controlled freez-
ing device (Air Liquide, Duesseldorf, Germany). Frozen
autologous tumor cells were stored at -196°C.
TrAb
TrAbs catumaxomab (anti-EpCAM × anti-CD3, removab®)
and ertumaxomab anti-Her2/neu × anti-CD3 (rexomun®)
were produced under GMP conditions as previously
described [11] and provided by Trion Pharma, Munich,
Germany.
Treatment
Patients received an i.p. catheter or port system for trAb
application. In order to achieve a standard minimal intra-
peritoneal volume of distribution, 1000 ml of balanced
electrolyte solution were infused i.p. before every trAb
application. TrAb were administered via the i.p. catheter
as a continuous infusion over 6 hours. In order to prevent
clinical symptoms within the known antibody treatment-
associated „cytokine release syndrome“ [24], pre-medica-
tion consisted of paracetamole supp. 1000 mg and
dimetindene i.v. 50 mg, applicated 30 min before trAb-
infusion.
Patients received three escalating doses of trAb (10, 20, 40
μg of EpCAM × CD3; or 10, 40, 80 μg of HER2/neu ×
CD3). Between two trAb applications, an interval of 2 to
3 days was inserted. The first application consisted of 10
μg of trAb. Criteria for the next trAb application were well-
being of the patient, leucocyte counts < 13 G/L and body
temperature < 37.5° for at least 12 hours. Dose reduction
was dependent on the individual reaction to the prior
dose, i.e. inflammatory reactions and side effects.
Antigen boost – Vaccination
Restimulation was performed by exposition of the
patients to autologous tumor cells and trAb 30 days after
the last i.p. infusion. Cryo-conservated autologous tumor
cells were rapidly thawed in a 37°C water bath and
washed in balanced electrolyte solution, followed by a
100 gray irradiation. 10 × 106 autologous PBMC were iso-
lated by a standard Ficoll-Hypaplaque (PAN Biotech, Aid-
enbach, Germany) density centrifugation technique.
PBMC and 1 × 106 autologous tumor cells were resus-
pended in a balanced electrolyte solution and incubated
in vitro for 30 minutes together with 3 μg of trAb anti-
EpCAM × anti-CD3 or anti-HER2/neu × anti-CD3
depending on the individual antigen expression of autol-
ogous tumor cells. The vaccination was performed by an
intradermal injection at two sites on both limbs.
Evaluation of immunological reactivity
In order to compare immune reactivity by CD4+/CD8+ T-
lymphocytes against autologous tumor cells, venous
blood samples were taken before commencing therapy
and 7 to 10 days after boost vaccination. 1 × 107 PBMC
were isolated by Ficoll-Hypaplaque density centrifuga-
tion. PBMC were stimulated in 24 well plates with autol-
ogous tumor cells only. After an 8 hour stimulation
period, the Miltenyi Biotec® IFN-γ Secretion Assay was per-
formed according to the manufacturers manual (Miltenyi
Biotech, Bergisch Gladbach, Germany), using anti-human
CD4 and anti-human CD8 antibodies (Coulter Immu-
notech, Krefeld, Germany). FACS analysis was performed
with a FACSCalibur Flow cytometer (Becton Dickinson,
Heidelberg, Germany) using CellQuest Pro and WinMDI
software. Unstimulated PBMC and PBMC after incuba-
tion with allogeneic EpCAM+ HT-29 (ATCC Nr. CCL-244)
or HER2/neu+ SK-BR-3 carcinoma cells (ATCC Nr. HTB-
30) were used as negative controls.
Clinical patient evaluation/toxicity and safety evaluation
Careful patient monitoring was applied throughout the
study. Clinical evaluation, including medical history and
general physical exam, was performed at baseline andJournal of Experimental & Clinical Cancer Research 2009, 28:18 http://www.jeccr.com/content/28/1/18
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defined days during treatment (day of trAb infusion and
the following day; day of restimulation and the following
day). Patients were monitored for adverse events accord-
ing to the National Cancer Institute common toxicity cri-
teria during each visit. Standard laboratory parameters
and vital signs were tested before and after treatment Lab-
oratory testing included complete blood count, electro-
lytes, creatinine, bilirubin, transaminases, and tumor
marker (CA19-9 for gastric carcinoma, CA125 for ovarian
carcinoma, CEA and CA125 for CUP). In addition,
patients during trAb therapy were daily monitored for sys-
temic cytokine responses. Blood samples were taken
before, 24 hours and 48 h after every trAb application.
Serum levels of IL-6, TNF-α, and sIL-2R were measured by
ELISA (Biosource, Fleurs, Belgium). Immune reaction to
mouse IgG was assessed by ELISA measurement of human
anti-mouse antibody reaction (HAMA) before and 4
weeks after therapy.
Response was evaluated by computed tomography two to
three months after trAb treatment and every two to three
months until tumor progression.
Statistical analysis
Analysis of cytokine levels was performed using the Wil-
coxon signed rank test. Correlation analysis was done by
the chi-square contingency analysis. All tests were calcu-
lated by SAS statistical software using a Windows XP com-
puter system.
Results
Patients' characteristics
Nine patients were treated between February 2005 and
December 2007. Prior to study treatment, 6 patients
underwent surgical resection with curative intent, 8
patients received chemotherapy. Four patients presented
with synchronous PC, whereas five developed PC after
surgery and chemotherapy. One patient was diagnosed
with PC of carcinoma of unknown primary (CUP) during
elective laparoscopic cholecystectomy. The patients'
demographic and primary treatment parameters are listed
in Table 1.
Application of trAb and monitoring
All nine patients received i.p. trAb applications. No dose
escalation for the third application was performed in
patient A because of side effects. In patient C, reduced
starting dose of 5 μg was in respect of a body weight of 43
kg only; Patient F refused the third application of trAb. For
detailed therapy of each patient, please see Table 2 and
Table 3.
TrAb treatment was accompanied by transient fever (up to
40.4°C) after 9 applications. The fever developed six to
ten hours after trAb infusion and disappeared within the
next day. Metamizole (1000 mg) was given in these cases.
Six patients complained about abdominal pain; four
patients had vomiting and required treatment with
Dimenhydrinate. No patient required ICU admittance.
Elevated liver enzymes, elevated levels of γ-glutamyl trans-
ferase and alkaline phosphatase were observed after trAb
application. These laboratory changes disappeared spon-
taneously within the treatment intervals.
TrAb treatment was followed by an elevation of serum lev-
els of IL-6, TNF-α, and soluble IL-2 receptor one day after
treatment. The slight decrease on the second day after
every trAb application was statistically not significant (Fig-
ure 1A, 1B). The inflammatory cytokine IL-6 showed a
substantial increase after the first trAb infusion only;
despite trAb dose escalation there were only moderate
Table 1: Patients' characteristics
Pat. Age Sex Tumor entity TNM stage 
primary
Surgical 
therapy 
primary 
tumor
Chemothera
py before 
trAb
Radiation 
before trAb
EpCAM 
expression
HER2/neu 
expression
A 31 f Gastric pT4pN3M0 Gastrectomy + + + +
B 64 f Ovarian pT3pN0M0 Adnexectomy, 
resect. of liver 
met.
+-+-
C 50 f CUP - - - - + -
D 62 f Ovarian pT3pN2M0 Adnexectomy + - - +
E 59 m Gastric pT4pN2M1 Gastrectomy + - + +
F 35 f Gastric pT3pN0M0 Gastrectomy + - + -
G3 8 f G a s t r i c T 3 N + M 1 - + - + -
H5 1 m G a s t r i c T 3 N + M 1 - + - + -
I 62 m Gastric pT3pN2M1 Gastrectomy + - + -
EpCAM or HER2/neu expression of autologous tumor cells was done by APAAP immunohistochemical staining. EpCAM+ or HER2/neu+: > 10% 
stained cells in autologous tumor cell preparations; CUP = carcinoma of unknown primary.Journal of Experimental & Clinical Cancer Research 2009, 28:18 http://www.jeccr.com/content/28/1/18
Page 5 of 10
(page number not for citation purposes)
increases after the following two applications (Figure 1C).
TNF-α was increased after every trAb application, fol-
lowed by a slight decrease on day 2. The soluble IL2-recep-
tor (sIL2R) serum level, which indicates T-cell activation,
analogously increased after each trAb application. Com-
paring the sIL2R level on day 1 after trAb application, the
maximum sIL2R level was found after the third trAb appli-
cation, indicating an ongoing and increasing cellular
immune activation during trAb therapy.
HAMA was measured after trAb therapy in 7 of 9 patients.
In all these patients, HAMA was significantly increased
(above the threshold of 40 ng/ml), representing an immu-
nological reaction (Table 4).
Immunological anti-tumor reactivity
All patients were restimulated 4 weeks after i.p.-applica-
tion of trAb. Patients revealed a base value of 0.4%
(mean) CD4+/CD8+ IFN-γ secreting T-lymphocytes in
PBMC before trAb-treatment. Five of nine patients
showed an increase of IFN-γ secreting T-lymphocytes,
reflecting autologous anti-tumor reactivity (Figure 2). In
these 5 patients, the number of tumor reactive T-lym-
phocytes increased from baseline value of 0.4% to 2.9%
(mean) after trAb therapy and restimulation. All control
experiments with unstimulated PBMC or PBMC incu-
bated with allogeneic tumor cells showed no increase
compared to the corresponding baseline values. In patient
B, the IFN-γ secretion assay was performed twice after
intradermal restimulation (Figure 3). Here, IFN-γ secret-
ing T-lymphocytes increased from 0.4% before therapy to
2.8% after restimulation, followed by a value of 2.8% on
day 110 after stimulation, indicating long-term immu-
nity. This patient also had a substantial decrease of tumor
markers (CA 125 decreased from 57.8 U/ml to 29.7 U/
ml).
Clinical outcome
Study patients did not receive any other tumor specific
therapies during i.p. trAb infusion or antigen restimula-
tion. According to RECIST criteria, 5 of 9 patients (Patients
B, C, F, G, H) showed a clinically stable disease or partial
tumor regression with a mean time to progression of 3.6
months (range 1 to 6 months) without any further tumor
specific treatment.
Table 2: I.p. application of trAb anti-EpCAM and side effects
Pat. TrAb anti-EpCAM therapy (μg i.p./day) Cumulative dose Side effects
μgd a yμgd a yμgd a y ( μg)
A 10 1 20 5 20 9 50 Elev. of AP (3), γ-GT (4); fever (3); abdominal pain (3); vomiting (3)
B 10 1 20 6 40 9 70 Elev. of AP (2), bilirubin (2), γ-GT (3), GOT (3), GPT (3); fever (3); abd. 
pain (3); vomiting (2); allergic exanthema (2)
C 5 1 20 3 40 7 65 Fever (2)
F 10 1 20 5 - 30 Elev. of AP (2), PTT (2), GPT (3); fever (1); abdominal pain (3); 
vomiting (2)
G 10 1 20 5 40 10 70 Elev. of AP (1), bilirubin (2), γ-GT (3), GPT (3); fever (1); abdominal 
pain (3)
H 10 1 20 7 40 13 70 Elev. of AP (1), bilirubin (2), gGT (3), creatinine (2); fever (1); 
abdominal pain (3)
I 10 1 20 8 40 12 70 Elev. of AP (1); fever (2); vomiting (3)
Table 3: I.p. application of trAb anti-Her2/neu and side effects
Pat. TrAb anti Her2/neu therapy (μg i.p./day) Cumulative dose Side effects
μgD a yμgD a yμgd a y ( μg)
D 1 014 048 08 1 3 0 F e v e r  ( 1 )
E 1 014 068 08 1 3 0 F e v e r  ( 1 ) ;  abdominal pain (2)
Individual schedule of trAb therapy and side effects according to the National Cancer Institute (NCI) common toxicity criteria.Journal of Experimental & Clinical Cancer Research 2009, 28:18 http://www.jeccr.com/content/28/1/18
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Serum levels (mean, +/- SEM) of TNF-α (A), soluble IL-2R (B), and IL-6 (C) immediately before the first, second and third trAb  application, and corresponding serum levels on day one and two dafter trAb therapy Figure 1
Serum levels (mean, +/- SEM) of TNF-α (A), soluble IL-2R (B), and IL-6 (C) immediately before the first, sec-
ond and third trAb application, and corresponding serum levels on day one and two dafter trAb therapy. Serum 
levels were measured by ELISA (Biosource, Fleurs, Belgium). * p < 0.05.
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After trAb therapy and restimulation, overall survival was
8.0 months (median; range 1 to 31 months). 6 patients
received chemotherapy after trAb immunotherapy. In
none of the patients accumulation of malignant ascites
was observed after trAb therapy.
Discussion
The results of this pilot study on the i.p. application and
restimulation by trAb in patients with PC provide strong
evidence for the induction of specific immune reactions
against autologous tumor cells by T-lymphocytes upon
trifunctional antibody treatment. Further more the study
Table 4: Restimulation and response
Patient Increase of IFN-γ secreting T-
lymphocytes
HAMA (ng/ml) Chemotherapy after trAb 
therapy
Survival after trAb therapy 
(months)
A+ 8 0 1 - 1
B+ 2 3 0 + 2 1
C - 30512 + 31
D- n . d . - 4
E + 7870 + 7
F - 50730 + 12
G + 2540 + 15
H- 4 0 0 + 8
I+ n . d . - 7
Increase of IFN-γ secreting T-lymphocytes compared to baseline values before therapy. HAMA = human anti-mouse antibody reaction (values 
measured 4 weeks after trAb therapy).
Individual percentage values presenting the relative proportion of IFN-γ secreting T-lymphocytes in 10 × 106 PBMC after stim- ulation with 5 × 105 autologous tumor cells before and 3–4 weeks after trAb therapy using the Miltenyi IFN-γ secretion assay Figure 2
Individual percentage values presenting the relative proportion of IFN-γ secreting T-lymphocytes in 10 × 106 
PBMC after stimulation with 5 × 105 autologous tumor cells before and 3–4 weeks after trAb therapy using the 
Miltenyi IFN-γ secretion assay.
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confirmed the safety and feasibility data of i.p. application
of trAb in patients without accumulation of ascites.
TrAb application was accompanied with "immunologi-
cal" side effects like fever, elevation of inflammatory
markers and allergic skin reactions. Further symptoms like
abdominal pain and nausea could be attributed to the dis-
turbance of the peritoneum by trAb mediated local
inflammation. Transient elevation of liver enzymes, γ-
glutamyl transferase and alkaline phosphatase were
observed after application of the anti-EpCAM × anti-CD3
trAb, but were not correlated to clinical symptoms. As the
epithelium of the biliary system typically expresses the
EpCAM-antigen [25], this side effect could be presumably
attributed to a transient trAb-induced cholangitis. In sum-
mary, all these side effects are very well in concordance
with the recently published results of our studies investi-
gating the trAb therapy in malignant ascites [21,22].
Major aim of this study was to investigate the induction of
T-cell mediated immune responses to autologous tumor
cells by intraperitoneal treatment and restimulation, as
induction of long-term immunity by trifunctional anti-
bodies was successfully demonstrated in an animal model
[15]. In five out of nine patients, specific tumor reactive
CD4/CD8 + T lymphocytes were found in PBMC by the
IFN-γ secretion assay, demonstrating that i.p. trAb therapy
is able to induce a verifiable increase of autologous tumor
reactive T lymphocytes. Additionally, sIL-2 levels also
indicated T-cell activation. Therefore we conclude that for-
mation of the so called tri-cell-complex of T-lymphocytes,
tumor cells and accessory cells by trifunctional antibodies
may result in induction of T-cell mediated anti-tumor
reactivity.
Regarding the structural binding sites of trifunctional anti-
bodies, one of the unique capacities of trAb is to bind and
activate CD3+ lymphocytes and CD64+ accessory cells
simultaneously. Several previous studies were performed
using anti-CD3 × anti-tumor bispecific antibodies (bsAb)
in non Hodgkin's lymphoma and solid tumors like ovar-
ian and renal cell cancer [26-28]. But these studies but
were mainly limited by the lack of costimulary signals
after primary activation. In addition, CD64 was described
as an attractive target molecule for bsAb based immuno-
therapy of cancer [29]; anti-EpCAM × anti-CD64 bsAb
were characterized to mediate strong cytotoxicity in vitro
after GCSF and IFN-γ pre-stimulation of PBMC [30].
Moreover, two studies using the bsAb MDX-H210 (anti-
HER2/neu × anti CD64) demonstrated clinical feasibility
but limited clinical efficacy in several patients with a dos-
age 15 mg/m2 after GCSF or GMCSF stimulation [31,32].
In this context, it should be highlighted that trAb signifi-
cantly differ from all described bsAb constructs. TrAb con-
sist of the two potent subclasses mouse IgG2a and rat
IgG2b, which determine the unique effector functions. In
contrast to similar T-cell redirecting bsAb, this mechanism
does not depend on the addition of exogenous cytokines
Analysis of tumor reactive IFN-γ secreting CD4+/CD8+ T lymphocytes before trAb therapy and on day 39 and 110 after boost  stimulation in patient B using the Miltenyi IFN-γ secretion assay Figure 3
Analysis of tumor reactive IFN-γ secreting CD4+/CD8+ T lymphocytes before trAb therapy and on day 39 and 
110 after boost stimulation in patient B using the Miltenyi IFN-γ secretion assay.
Immunological reactivity of patient B:
Interferon-Ȗ secreting T-lymphocytes in PBMC
0, 4 % 2,8 % 2,8 %
CD4/CD8 FITC
Before trAb therapy Day 39 after restimulation Day 110 after restimulation
I
F
N
-
Ȗ
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or co-stimulation to provide full anti-tumor activity [14]
as the formation of a postulated tri-cell complex between
tumor cell, T-cell and accessory cell represents a fully self-
supporting system for efficient immune cell activation
[13].
PC is generally seen as terminal tumor stage with rapid
progression. Regarding the natural history of PC, where
exponential tumor growth is expected, the observed clini-
cal course with stable disease or partial tumor regression
in five patients and the observed mean survival of 11.8
months (median 8.0 months) after trAb therapy is
remarkable. None of the nine patients developed accumu-
lation of malignant ascites during therapy, which would
have been expected in 20 to 30% of patients with PC.
Although outcome is not the goal of this trial, compared
to a mean survival of 6 months (median 3.1 months)
from the landmark study by Sadeghi et al. in 370 patients
with PC [1] our results are promising.
In summary, our results demonstrate that trAb are capable
to induce specific tumor immunity against autologous
tumor cells. In addition to the well documented ability of
tumor cell destruction [21], especially this unique self-
supporting efficacy of trAb may provide a new concept in
the treatment of intraabdominal tumors. Ongoing studies
in early stages of PC and in patients with high risk for
development of peritoneal tumor disease will further eval-
uate the therapeutic impact of trAb.
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